中生制药(01177)盘中涨超4%,本月内累计涨幅已超30%。截至发稿,股价上涨3.88%,现报6.97港元,成交额4.23亿港元。
中国生物制药公布,全资附属公司礼新医药自主研发的创新药LM-350“CDH17 ADC”已获得美国食品药品监督管理局(FDA)的新药临床试验(IND)批件。LM-350是基于礼新医药新一代抗体偶联药物(ADC)平台LM-ADCTM开发的一款靶向CDH17的ADC。公司指,除LM-350外,集团还有5款抗体偶联药物(ADC)产品位于临床阶段。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.